Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$13.84
-0.2%
$14.35
$10.60
$38.12
$1.46B0.251.19 million shs487,087 shs
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
$2.65
$2.61
$1.04
$7.18
$125.13M1.38418,678 shsN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$12.44
-1.8%
$11.24
$8.18
$29.56
$951.03M2.15850,512 shs1.41 million shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$17.69
-1.6%
$15.11
$2.80
$8.97
$637.87M0.6337,931 shs1.11 million shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+6.83%-10.25%+21.19%-35.69%
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
0.00%0.00%0.00%0.00%0.00%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
0.00%-2.28%+4.01%+36.11%-38.54%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-1.61%+7.08%+23.36%+25.91%+69.12%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
1.4859 of 5 stars
3.40.00.00.01.92.50.0
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1.5771 of 5 stars
3.41.00.00.03.00.80.0
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.80
Moderate Buy$40.00189.02% Upside
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
0.00
N/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.83
Moderate Buy$29.59137.85% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SBTX, TRIL, NRIX, KNTE, and EWTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $26.00
7/10/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
7/10/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$30.00
6/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
6/5/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$48.00
4/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$41.00
4/29/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/21/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.84 per shareN/A
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
N/AN/AN/AN/A$5.06 per shareN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$54.55M17.43N/AN/A$5.85 per share2.13
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
-$116.27M-$2.78N/AN/AN/AN/A-62.31%-54.72%N/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$193.57M-$2.80N/AN/AN/A-234.57%-45.26%-34.71%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest SBTX, TRIL, NRIX, KNTE, and EWTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/9/2025Q2 2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.79-$0.52+$0.27-$0.52$16.26 million$44,056.00 billion
5/8/2025Q1 2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.45-$0.43+$0.02-$0.43N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
20.99
20.99
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
N/A
10.80
10.80
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
6.82
6.26
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82
CompanyEmployeesShares OutstandingFree FloatOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60105.20 million80.79 millionOptionable
Kinnate Biopharma Inc. stock logo
KNTE
Kinnate Biopharma
8447.22 million27.53 millionOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
30076.45 million70.79 millionOptionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

Recent News About These Companies

Trillium Therapeutics Stock Price History
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$13.84 -0.03 (-0.22%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$13.36 -0.48 (-3.50%)
As of 07/11/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Kinnate Biopharma stock logo

Kinnate Biopharma NASDAQ:KNTE

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$12.44 -0.23 (-1.82%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$12.54 +0.10 (+0.80%)
As of 07/11/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$17.69 -0.29 (-1.61%)
As of 07/11/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Trillium Therapeutics stock logo

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.